Navigation Links
Delcath to Present at the JMP Securities Healthcare Conference on September 28, 2011
Date:9/19/2011

ffer materially from those described. Factors that may cause such differences include, but are not limited to, uncertainties relating to the time required to build inventory and establish commercial operations in Europe, adoption, use and resulting sales, if any, for the Hepatic CHEMOSAT delivery system in the EEA, our ability to successfully commercialize the chemosaturation system and the potential of the chemosaturation system as a treatment for patients with terminal metastatic disease in the liver, acceptability of the Phase III clinical trial data by the FDA, our ability to address the issues raised in the Refusal to File letter received from the FDA and the timing of our re-submission of our NDA, re-submission and acceptance of the Company's NDA by the FDA, approval of the Company's NDA for the treatment of metastatic melanoma to the liver, adoption, use and resulting sales, if any, in the United States, approval of the current or future chemosaturation system for other indications, actions by the FDA or other foreign regulatory agencies, our ability to obtain reimbursement for the CHEMOSAT system, our ability to successfully enter into distribution and strategic partnership agreements in foreign markets and the corresponding revenue associated with such foreign markets, uncertainties relating to the results of research and development projects and future clinical trials, and uncertainties regarding our ability to obtain financial and other resources for any research, development and commercialization activities. These factors, and others, are discussed from time to time in our filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date they are made. We undertake no obligation to publicly update or revise these forward-looking statements to reflect events or circumstances after the date they are made.Contact Information:Investor Contact:

Media Contact
'/>"/>

SOURCE Delcath Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Delcath Expands Phase III Trial for Metastatic Melanoma to Include University of Maryland Medical Center
2. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
3. Delcath Expands Phase III Trial for Metastatic Melanoma to Include St. Lukes Cancer Center
4. Delcath Adds Dr. Pamela R. Contag to Its Board of Directors
5. Delcath Continues Expansion of Clinical Trial Centers Offering PHP(TM)
6. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
7. Data Safety Monitoring Board Unanimously Recommends Continuation of Delcaths Phase III Clinical Trial
8. Delcath Systems, Inc. Appoints Dr. Krishna Kandarpa its Executive Vice President R&D and Chief Medical Officer
9. Delcath Systems, Inc. Completes Phase III Study Enrollment
10. Delcath Systems Begins Data Analysis of Phase III Trial
11. Delcath Systems, Inc. to Present at the 12th Annual Needham Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... NEW YORK , Nov. 20, 2014  Market research ... as the "Year of The Buy, in the medical ... market for medical devices will produce just 3% growth ... competitive actions, including acquisitions of product lines and entrance ... an annual survey of medical devices, The Global ...
(Date:11/21/2014)... QC , Nov. 20, 2014 /CNW Telbec/ - ... to announce the following appointments: ... team in the newly created role of Chief Commercial ... BioPhotonic system using topical photoconverter gel for the treatment ... surgical and traumatic wounds, recently approved in ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Depomed, Inc. (NASDAQ: ... at the Piper Jaffray 26 th Annual Healthcare Conference in ... at the Piper Jaffray conference is scheduled for 8:00 am EST ... be webcast, and the webcast can be accessed via the Investor ... recording of the webcast will be archived for 30 days on ...
Breaking Medicine Technology:Kalorama: 2014 The "Year of The Buy" in Medical Device Industry 2KLOX Technologies announces executive appointments 2KLOX Technologies announces executive appointments 3KLOX Technologies announces executive appointments 4Depomed To Present At Piper Jaffray 26th Annual Healthcare Conference 2
... DIEGO, May 12, 2011 GT Life Sciences, Inc., ... issuance of Patent No. 7,856,317 for "SYSTEMS AND METHODS ... Patent and Trademark Office.  The ,317 patent has a ... novel claims to computer systems and complex modeling processes ...
... Reportlinker.com announces that a new ... its catalogue: Generic ... Focus on Super Generics and Biosimilars ... http://www.reportlinker.com/p0491876/Generic-Growth-Strategies---Manufacturers-to-Increase-Focus-on-Super-Generics-and-Biosimilars-to-Drive-Revenues.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Vitamin_and_Supplement Generic ...
Cached Medicine Technology:GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling 2GT Life Sciences Broadens Intellectual Property Portfolio with Issuance of U.S. Patent on Core Computational Systems and Methods for Genomic-based Metabolic Modeling 3Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 2Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 3Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 4Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 5Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 6Reportlinker Adds Generic Growth Strategies - Manufacturers to Increase Focus on Super Generics and Biosimilars to Drive Revenues 7
(Date:11/21/2014)... For many busy people, having their missing or ... of recovery from dental surgery that have traditionally been required ... of their youthful appearance. , But the dental implant ... and Woodland Hills, Calif., can provide someone with a full ... where the patient’s bone has deteriorated. , Dr. Saj Jivraj ...
(Date:11/21/2014)... OR (PRWEB) November 21, 2014 Even with ... always something to learn and room for growth, participating in ... returned from State Farm’s National Convention, a networking event with ... around the country, bringing back the latest and greatest in ... may have spotted Kirk and his team (Stacy, Anthony, Reina ...
(Date:11/21/2014)... West Palm Beach, FL (PRWEB) November 21, 2014 ... Administration report issued on June 11th, 2014, ... Takata Corporation can rupture when the airbag inflates. The ... break into metal shrapnel, and the metal shards may ... anyone within the vehicle’s cabin. , According to ...
(Date:11/21/2014)... HealthDay Reporter THURSDAY, Nov. 20, ... may help preserve thinking skills and memory as workers ... compared IQ scores obtained around age 11 from more ... scores around age 70. The scientists found that those ... thinking even years after retirement. Researchers from ...
(Date:11/21/2014)... 20, 2014 (HealthDay News) -- While levels of testosterone ... women,s sex lives, their emotional health and quality of ... new study. Testosterone is the main sex hormone ... amounts of the hormone, the researchers noted. The ... taking part in a long-term study of women,s health. ...
Breaking Medicine News(10 mins):Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 2Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 3Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 4Health News:Anacapa Dental Art Institute Prosthodontists Develop New Technique to Offer Younger Appearance in Just One Visit 5Health News:Kirk Martin Insurance Agency Goes Local and National with State Farm 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 2Health News:Takata Airbag Recall Class Action Lawsuit Resource Released by Florida Injury Attorney 3Health News:Could Your Job Help Preserve Your Aging Brain? 2Health News:Could Your Job Help Preserve Your Aging Brain? 3Health News:Testosterone Plays Minor Role in Older Women's Sex Lives, Study Finds 2
... , , SAN FRANCISCO, July 31 ... announced the execution of a letter of intent (LOI) to collaborate ... diagnostic testing and banking of advanced-stage Lung Cancer tissues. ... ) , , Specific molecular features ...
... times more likely to have chronic health conditions, less ... lower incomes than their siblings, according to a study ... the National Cancer Institute . This study was ... for neuroblastoma survivors. Caroline Laverdiere, M.D., of the ...
... , TITUSVILLE, N.J., July 31 The ... palmitate) extended-release injectable suspension for the acute and maintenance treatment ... injectable atypical antipsychotic approved in the U.S. for this use. ... in the U.S. , , An estimated ...
... health conditions are spread, study finds , FRIDAY, July 31 ... surgery doesn,t appear to increase one,s chances of having long-term ... study of 1,062 people who required a transfusion before, during ... of the patients were still alive a decade after the ...
... , GAINESVILLE, Fla., July 31 ... correction of facial wrinkles in healthy patients in the USA. It ... Surgeon, has 7 years of experience with the product while abroad. ... , Sanofi-aventis is a leading global pharmaceutical company. The ...
... 31 In a post-recession America, even though as a nation income ... crushing burden of health care costs and will watch their standards of ... the New England Journal of Medicine (NEJM) by Daniel ... University of Pennsylvania,s Leonard Davis Institute of Health Economics. , ...
Cached Medicine News:Health News:Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc. 2Health News:Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc. 3Health News:Addario Lung Cancer Medical Institute Announces Diagnostic Screening and Clinical Research Collaborations With Response Genetics, Inc. 4Health News:Long-term health and social outcomes for neuroblastoma survivors 2Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 2Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 3Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 4Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 5Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 6Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 7Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 8Health News:FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia 9Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 2Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 3Health News:Post-Recession Incomes Will Be Hit Hard by Health Care Spending for Middle Class Working Families, PENN Analysis Shows 4
Due to its thick formula, REFRESH CELLUVISC Lubricant Eye Drops is ideal for persistent dry eye conditions. REFRESH CELLUVISC provides lasting relief and protection for dry, scratchy eyes....
... solution is an anti-infective prescription ... may instruct you to use ... infection caused by bacteria. Bacterial ... the 2 types of eye ...
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
ALPHAGAN® (brimonidine tartrate ophthalmic solution) 0.2% is indicated for lowering IOP in patients with open-angle galucoma or ocular hypertension....
Medicine Products: